DRUG vs. SNPX, GTBP, CPHI, SONN, SNGX, PXMD, PTPI, KA, SEEL, and KZIA
Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Synaptogenix (SNPX), GT Biopharma (GTBP), China Pharma (CPHI), Sonnet BioTherapeutics (SONN), Soligenix (SNGX), PaxMedica (PXMD), Petros Pharmaceuticals (PTPI), Kineta (KA), Seelos Therapeutics (SEEL), and Kazia Therapeutics (KZIA). These companies are all part of the "pharmaceutical preparations" industry.
Synaptogenix (NASDAQ:SNPX) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.
10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 4.3% of Synaptogenix shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.
Synaptogenix has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
In the previous week, Synaptogenix had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 3 mentions for Synaptogenix and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of -0.33 beat Synaptogenix's score of -1.00 indicating that Synaptogenix is being referred to more favorably in the media.
Bright Minds Biosciences' return on equity of -22.50% beat Synaptogenix's return on equity.
Synaptogenix received 1 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users.
Summary
Synaptogenix beats Bright Minds Biosciences on 6 of the 11 factors compared between the two stocks.
Get Bright Minds Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bright Minds Biosciences Competitors List
Related Companies and Tools
